Mark Livingston Sells 2,517 Shares of Progyny (NASDAQ:PGNY) Stock

Progyny, Inc. (NASDAQ:PGNY) CFO Mark Livingston sold 2,517 shares of the company’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $25.50, for a total transaction of $64,183.50. Following the completion of the transaction, the chief financial officer owned 74,688 shares of the company’s stock, valued at approximately $1,904,544. The trade was a 3.26% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Progyny Price Performance

Shares of Progyny stock traded up $0.38 during trading hours on Friday, hitting $25.86. The company had a trading volume of 1,207,696 shares, compared to its average volume of 1,553,521. The company’s 50-day moving average is $20.42 and its two-hundred day moving average is $22.27. Progyny, Inc. has a twelve month low of $16.10 and a twelve month high of $28.75. The company has a market cap of $2.03 billion, a P/E ratio of 33.58, a price-to-earnings-growth ratio of 1.33 and a beta of 1.03.

Progyny (NASDAQ:PGNY) last issued its earnings results on Thursday, May 7th. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.24. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The business had revenue of $328.50 million during the quarter, compared to analysts’ expectations of $326.47 million. During the same quarter in the prior year, the business posted $0.17 EPS. The company’s revenue for the quarter was down 26.4% on a year-over-year basis. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Sell-side analysts expect that Progyny, Inc. will post 1.12 EPS for the current year.

Progyny declared that its Board of Directors has initiated a stock repurchase plan on Tuesday, May 26th that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the company to buy up to 10.3% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

Several research firms recently commented on PGNY. Wall Street Zen upgraded shares of Progyny from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. KeyCorp reduced their price target on shares of Progyny from $32.00 to $28.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Zacks Research upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a research report on Thursday, May 7th. Bank of America upped their price target on shares of Progyny from $29.00 to $31.00 and gave the company a “buy” rating in a research report on Tuesday. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 price target on shares of Progyny in a research report on Friday, March 6th. One analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $29.67.

Institutional Trading of Progyny

Institutional investors and hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System lifted its position in Progyny by 0.7% during the second quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock valued at $1,549,000 after buying an additional 457 shares in the last quarter. Teza Capital Management LLC lifted its position in Progyny by 5.4% during the second quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after buying an additional 516 shares in the last quarter. Aristides Capital LLC lifted its position in Progyny by 4.6% during the third quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock valued at $257,000 after buying an additional 528 shares in the last quarter. Leibman Financial Services Inc. lifted its position in Progyny by 1.2% during the fourth quarter. Leibman Financial Services Inc. now owns 46,435 shares of the company’s stock valued at $1,192,000 after buying an additional 528 shares in the last quarter. Finally, Oxford Asset Management LLP lifted its position in Progyny by 4.3% during the second quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after buying an additional 531 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company’s stock.

About Progyny

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.